https://tonic.inserm.fr/wp-content/uploads/2019/09/equipe-femme-defaut-150x150.jpg
 

Fabienne ORY

PH

    Publications rédigées ou co-rédigées

  • > 13- Expanding the clinical spectrum of STIP1 homology and U-box containing protein 1-associated ataxia.

    Ravel JM, Benkirane M, Calmels N, Marelli C, Ory-Magne F, Ewenczyk C, Halleb Y, Tison F, Lecocq C, Pische G, Casenave P, Chaussenot A, Frismand S, Tyvaert L, Larrieu L, Pointaux M, Drouot N, Bossenmeyer-Pourié C, Oussalah A, Guéant JL, Leheup B, Bonnet C, Anheim M, Tranchant C, Lambert L, Chelly J, Koenig M, Renaud M.
    Voir la publication

    J Neurol. 2021 Jan 8. doi: 10.1007/s00415-020-10348-x.
  • > 2- Personality dimensions of patients can change during the course of parkinson’s disease.

    Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland AS, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou N, Belamri L, Tir M, Marques AR, Thobois S, Eusebio A, Corvol JC, Devos D, Brefel-Courbon C; PREDI-STIM study group.
    Voir la publication

    PLoS One. 2021 Jan 7;16(1):e0245142. doi: 10.1371/journal.pone.0245142.
  • > 32- Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson’s Disease Patients (PSYCHO-STIM).

    Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, Marques AR, Danaila T, Eusebio A, Devos D, Brefel-Courbon C; PREDI-STIM study group.
    Voir la publication

    J Parkinsons Dis. 2020 May 16. doi: 10.3233/JPD-191903.
  • > 54- Drug-induced parkinsonism

    Ory-Magne F.
    Voir la publication

    Rev Prat. 2020 May;70(5):475-478.
  • > 29- Repetitive transcranial magnetic stimulation for functional tremor: A randomized, double-blind, controlled study.

    Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, Simonetta-Moreau M.

    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27727.
  • > 63- Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type.

    Vergnet S, Hives F, Foubert-Samier A, Payoux P, Fernandez P, Meyer M, Dupouy J, Brefel-Courbon C, Ory-Magne F, Rascol O, Tison F, Pavy-Le Traon A, Meissner WG.
    Voir la publication

    Parkinsonism Relat Disord. 2019 Jun;63:199-203. doi: 10.1016/j.parkreldis.2019.02.006. Epub 2019 Feb 5.
  • > 57- Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.

    Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group.
    Voir la publication

    Neurology. 2019 Mar 5;92(10):e1109-e1120. doi: 10.1212/WNL.0000000000007037. Epub 2019 Feb 8. Erratum in: Neurology. 2019 Jun 11;92(24):1166.
  • > 6- Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson’s disease: a correlation study.

    Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, Kas A, Salabert AS, Ory-Magne F, Payoux P, Brefel-Courbon C.

    J Neural Transm (Vienna). 2019 Jan 31. doi: 10.1007/s00702-019-01974-5.
  • > 28- Cognitive complaint in early Parkinson’s disease: A pilot study.

    Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.

    Acta Neurol Scand. 2018 Jan;137(1):59-66. doi: 10.1111/ane.12808. Epub 2017 Aug 22.
  • > 66- Abnormal pain perception in patients with Multiple System Atrophy.

    Ory-Magne F, Pellaprat J, Harroch E, Galitzsky M, Rousseau V, Pavy-Le Traon A, Rascol O, Gerdelat A, Brefel-Courbon C.

    Parkinsonism Relat Disord. 2017 Dec 8. pii: S1353-8020(17)30827-1. doi: 10.1016/j.parkreldis.2017.12.001.
  • > 41- Cognitive complaint in early Parkinson’s disease: A pilot study.

    Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.

    Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12808.
  • > 45- Parkinson’s patients can rely on perspective cues to perceive 3D space.

    Séverac Cauquil A, Ory-Magne F, Jardiné V, Galitzky M, Rosito M, Brefel-Courbon C, Celebrini S.

    Brain Res. 2017 May 15;1663:161-165. doi: 10.1016/j.brainres.2017.03.017. Epub 2017 Mar 19.
  • > 18- Other care in Parkinson’s disease: Psychological, rehabilitation, therapeutic education and new technologies.

    Dupouy J, Ory-Magne F, Brefel-Courbon C.

    Presse Med. 2017 Mar;46(2 Pt 1):225-232. doi: 10.1016/j.lpm.2016.11.009. Epub 2016 Dec 28. Review. French.
  • > 14- A longitudinal follow-up study of the quantification of dopamine transporters with 123I-Ioflupane (DaTscan)

    H. Fayolle, P. Gantet, A.S. Salabert, J. Delrieu, C. Brefel-Courbon, F. Ory-Magne, T. Voisin, P. Payoux

    Médecine Nucléaire 41 (2017) 36-41
  • > 56- Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients: A Randomized Controlled Trial.

    Canivet C, Costa N, Ory-Magne F, Arcari C, Mohara C, Pourcel L, Derumeaux H, Bérard E, Bourrel R, Molinier L, Brefel-Courbon C.

    PLoS One. 2016 Sep 29;11(9):e0162646. doi: 10.1371/journal.pone.0162646.
  • > Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson’s disease.

    Pellaprat J, Ory-Magne F, Canivet C, Simonetta-Moreau M, Lotterie JA, Radji F, Arbus C, Gerdelat A, Chaynes P, Brefel-Courbon C.

    Parkinsonism Relat Disord. 2014 Jun;20(6):662-4. doi: 10.1016/j.parkreldis.2014.03.011.
  • > [A therapeutic educational program in Parkinson’s disease: ETPARK].

    Ory Magne F, Arcari C, Canivet C, Sarrail M, Fabre MH, Mohara C, Brefel Courbon C.

    Rev Neurol (Paris). 2014 Feb;170(2):128-33. doi: 10.1016/j.neurol.2013.08.007. French.
  • > Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.

    Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network..

    Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050.